Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
暂无分享,去创建一个
D. Esseltine | P. Ganly | N. Munshi | P. Richardson | Shaji K. Kumar | S. Rajkumar | P. Moreau | H. Avet-Loiseau | C. Langer | Jianchang Lin | T. Masszi | S. Badola | M. Cavo | N. Bahlis | K. Luptakova | L. Pour | A. D. Bacco | D. Berg | H. Velde | L. Viterbo | Jacob Zhang | L. Shen | Bin Li | Ling Wang